David Steensma
Overview
Explore the profile of David Steensma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
445
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Steensma D
J Clin Oncol
. 2023 May;
41(19):3557-3558.
PMID: 37220316
@DavidSteensma The author describes the complex emotions that result from encountering graves of former patients on walks through a cemetery in his New England hometown. He reflects the joy that...
2.
Patnaik M, Zeidan A, Padron E, Platzbecker U, Sallman D, DeZern A, et al.
Leukemia
. 2022 Nov;
36(12):2934-2938.
PMID: 36335264
No abstract available.
3.
Komrokji R, Al Ali N, Padron E, Lancet J, Nazha A, Steensma D, et al.
Leuk Lymphoma
. 2021 Jun;
62(11):2762-2767.
PMID: 34114922
Hypomethylating agents (HMAs) are the standard of care for higher risk MDS (HR-MDS) patients. The current dogma is to begin HMA therapy in all HR-MDS patients at the time of...
4.
Park S, Hamel J, Toma A, Kelaidi C, Thepot S, Diez Campelo M, et al.
Leuk Res
. 2020 Nov;
99:106472.
PMID: 33212326
No abstract available.
5.
Libby P, Sidlow R, Lin A, Gupta D, Jones L, Moslehi J, et al.
J Am Coll Cardiol
. 2019 Jul;
74(4):567-577.
PMID: 31345432
A novel, common, and potent cardiovascular risk factor has recently emerged: clonal hematopoiesis of indeterminate potential (CHIP). CHIP arises from somatic mutations in hematopoietic stem cells that yield clonal progeny...
6.
Haase D, Stevenson K, Neuberg D, Maciejewski J, Nazha A, Sekeres M, et al.
Leukemia
. 2019 Jan;
33(7):1747-1758.
PMID: 30635634
Risk stratification is critical in the care of patients with myelodysplastic syndromes (MDS). Approximately 10% have a complex karyotype (CK), defined as more than two cytogenetic abnormalities, which is a...
7.
Benton C, Khan M, Sallman D, Nazha A, Nogueras Gonzalez G, Piao J, et al.
Am J Hematol
. 2018 Jul;
93(10):1245-1253.
PMID: 30051599
The International Prognostic Scoring System-Revised (IPSS-R) is one standard for myelodysplastic syndrome (MDS) risk stratification. It divides patients into five categories including an intermediate subset (IPSS-R int-risk). Outcomes and clinical...
8.
Jain N, Steensma D, Stewart D, Kantarjian H
J Oncol Pract
. 2016 Feb;
12(4):283-5.
PMID: 26907450
No abstract available.
9.
Jones G, Tefferi A, Steensma D, Kantarjian H
Am J Med
. 2015 Jul;
128(11):1162-4.
PMID: 26184683
No abstract available.
10.
Wu S, Li L, Kopp N, Montero J, Chapuy B, Yoda A, et al.
Cancer Cell
. 2015 Jul;
28(1):29-41.
PMID: 26175414
A variety of cancers depend on JAK2 signaling, including the high-risk subset of B cell acute lymphoblastic leukemias (B-ALLs) with CRLF2 rearrangements. Type I JAK2 inhibitors induce paradoxical JAK2 hyperphosphorylation...